CN111225680A - 非酒精性脂肪性肝病的治疗药物 - Google Patents

非酒精性脂肪性肝病的治疗药物 Download PDF

Info

Publication number
CN111225680A
CN111225680A CN201880067640.0A CN201880067640A CN111225680A CN 111225680 A CN111225680 A CN 111225680A CN 201880067640 A CN201880067640 A CN 201880067640A CN 111225680 A CN111225680 A CN 111225680A
Authority
CN
China
Prior art keywords
polypeptide
amino acid
group
weeks
hbv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880067640.0A
Other languages
English (en)
Inventor
刘宏利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Hep Pharmaceutical Co ltd
Original Assignee
Shanghai Hep Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Hep Pharmaceutical Co ltd filed Critical Shanghai Hep Pharmaceutical Co ltd
Publication of CN111225680A publication Critical patent/CN111225680A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/02—Hepadnaviridae, e.g. hepatitis B virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

本发明提供了非酒精性脂肪性肝病的治疗药物。具体而言，本发明提供了含有衍生自乙肝病毒(HBV)的氨基酸序列的多肽或其药物组合物在制备治疗或预防非酒精性脂肪性肝病的药物中的应用。

Description

PCT国内申请，说明书已公开。

Claims (10)

  1. PCT国内申请，权利要求书已公开。
CN201880067640.0A 2017-10-18 2018-10-18 非酒精性脂肪性肝病的治疗药物 Pending CN111225680A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2017109725486 2017-10-18
CN201710972548.6A CN109675016A (zh) 2017-10-18 2017-10-18 非酒精性脂肪性肝病的治疗药物
PCT/CN2018/110770 WO2019076331A1 (zh) 2017-10-18 2018-10-18 非酒精性脂肪性肝病的治疗药物

Publications (1)

Publication Number Publication Date
CN111225680A true CN111225680A (zh) 2020-06-02

Family

ID=66174301

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201710972548.6A Pending CN109675016A (zh) 2017-10-18 2017-10-18 非酒精性脂肪性肝病的治疗药物
CN201880067640.0A Pending CN111225680A (zh) 2017-10-18 2018-10-18 非酒精性脂肪性肝病的治疗药物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201710972548.6A Pending CN109675016A (zh) 2017-10-18 2017-10-18 非酒精性脂肪性肝病的治疗药物

Country Status (3)

Country Link
US (1) US20200338158A1 (zh)
CN (2) CN109675016A (zh)
WO (1) WO2019076331A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112138008A (zh) * 2020-09-30 2020-12-29 郑州大学 洛美他派在制备抗肿瘤药物中的应用
CN113993883A (zh) * 2019-08-29 2022-01-28 渥太华Hdl药物研发公司 一种多肽及其应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200157541A1 (en) * 2018-11-19 2020-05-21 Exosome Therapeutics, Inc. Exosome loaded therapeutics for the treatment of non-alcoholic steatohepatitis, diabetes mellitus type 1 and type 2, atherosclerotic cardiovascular disease, and alpha 1 antitrypsin deficiency
GB202003722D0 (en) * 2020-03-14 2020-04-29 Martin John Francis Treatment
CN111494641B (zh) * 2020-04-22 2021-08-03 南开大学 肿瘤微环境响应性的表面电荷可反转纳米药物递送载体

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103402545A (zh) * 2011-02-10 2013-11-20 海德堡鲁普雷希特卡尔斯大学 疏水性经修饰肽及其在肝特异性靶向中的用途
CN104274827A (zh) * 2013-07-01 2015-01-14 上海贺普药业股份有限公司 贺普拉肽的制剂
CN105377246A (zh) * 2013-04-22 2016-03-02 卡迪拉保健有限公司 针对非酒精性脂肪性肝病(nafld)的新组合物
WO2017102906A1 (en) * 2015-12-16 2017-06-22 Ruprecht-Karls-Universität Heidelberg Cyclic ntcp-targeting peptides and their uses as entry inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103402545A (zh) * 2011-02-10 2013-11-20 海德堡鲁普雷希特卡尔斯大学 疏水性经修饰肽及其在肝特异性靶向中的用途
CN105377246A (zh) * 2013-04-22 2016-03-02 卡迪拉保健有限公司 针对非酒精性脂肪性肝病(nafld)的新组合物
CN104274827A (zh) * 2013-07-01 2015-01-14 上海贺普药业股份有限公司 贺普拉肽的制剂
WO2017102906A1 (en) * 2015-12-16 2017-06-22 Ruprecht-Karls-Universität Heidelberg Cyclic ntcp-targeting peptides and their uses as entry inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
李广智等: "《乙型肝炎 第二版》", 中国医药科技出版社, pages: 110 - 111 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113993883A (zh) * 2019-08-29 2022-01-28 渥太华Hdl药物研发公司 一种多肽及其应用
CN112138008A (zh) * 2020-09-30 2020-12-29 郑州大学 洛美他派在制备抗肿瘤药物中的应用
CN112138008B (zh) * 2020-09-30 2022-06-17 郑州大学 洛美他派在制备抗肿瘤药物中的应用

Also Published As

Publication number Publication date
WO2019076331A1 (zh) 2019-04-25
US20200338158A1 (en) 2020-10-29
CN109675016A (zh) 2019-04-26

Similar Documents

Publication Publication Date Title
CN111225680A (zh) 非酒精性脂肪性肝病的治疗药物
US7642241B2 (en) Methods of enhancing functioning of the large intestine
CN104583234A (zh) 毒蜥外泌肽-4肽类似物
US11179440B2 (en) Pharmaceutical composition containing FGF21 mutant fusion protein and method for treating hepatitis, hepatic fibrosis, and hepatic cirrhosis
WO2017112889A1 (en) Long-acting glp-1r agonist as a therapy of neurological and neurodegenerative conditions
CN107454846A (zh) 修饰的肽及其治疗慢性炎性疾病的用途
US20230414706A1 (en) Compositions and methods for treating metabolic diseases
JP2016515123A (ja) Ｐｌａ２ｇ１２ａポリペプチド及びｐｌａ２ｇ１２ａ変異ポリペプチドを使用して代謝障害を治療する方法
JP6262661B2 (ja) 筋萎縮性側索硬化症治療剤
US20200316166A1 (en) Drug and Method for Treating Liver Diseases Related to Hepatitis B Viruses in Full-Dose Condition
CN115124602B (zh) Gip和glp-1的双受体激动剂、药物组合物及用途
CN113164549A (zh) 包含针对Fas信号传导的抑制肽的用于预防或治疗肥胖症、脂肪肝或脂肪性肝炎的药物组合物
JP2012517459A (ja) 代謝障害治療のためのカルジオトロフィン１の使用
KR101645015B1 (ko) Fpr2를 활성화하는 물질을 포함하는, 인슐린 저항성 관련 질환 치료용 조성물
US9610324B2 (en) Apolipoprotein mixtures
WO1999058144A1 (en) Methods of enhancing functioning of the large intestine
US9340593B2 (en) Method of treating diabetes by a CTRP12 polypeptide
WO2023246928A1 (zh) 一种改进的glp-1受体激动剂的融合蛋白和应用
NZ794313A (en) Pharmaceutical composition for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis comprising fusion proteins
EA043417B1 (ru) АГОНИСТ ДЛИТЕЛЬНОГО ДЕЙСТВИЯ GLP-1r КАК ТЕРАПИЯ ДЛЯ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ И НЕЙРОДЕГЕНЕРАТИВНЫХ ПАТОЛОГИЧЕСКИХ СОСТОЯНИЙ

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination